登录 查看组织和合同定价。
选择尺寸
关于此项目
经验公式(希尔记法):
C36H48N6O9 · xC2HF3O2
化学文摘社编号:
分子量:
708.80 (free base basis)
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
SMILES string
N3([C@@H](CCC3)C(=O)O)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)Cc1ccc(cc1)NC(=O)Nc2c(cccc2)C)CC(C)C)CC(=O)O)C(C)C
InChI
1S/C36H48N6O9/c1-20(2)17-26(38-29(43)18-23-12-14-24(15-13-23)37-36(51)40-25-10-7-6-9-22(25)5)32(46)39-27(19-30(44)45)33(47)41-31(21(3)4)34(48)42-16-8-11-28(42)35(49)50/h6-7,9-10,12-15,20-21,26-28,31H,8,11,16-19H2,1-5H3,(H,38,43)(H,39,46)(H,41,47)(H,44,45)(H,49,50)(H2,37,40,51)/t26-,27-,28-,31-/m0/s1
InChI key
NVVGCQABIHSJSQ-KFZSMJGVSA-N
assay
≥97% (HPLC)
form
film, lyophilized powder
storage condition
desiccated
color
white to beige
shipped in
wet ice
storage temp.
−20°C
Biochem/physiol Actions
BIO 1211 is a selective, tight-binding α4β1 (VLA-4, very late antigen-4; koff = 1.4 x 10-4/s, KD = 70 pM) integrin antagonist (VCAM-Ig Jurkat surface binding IC50 = 1 nM; integrin-mediated cell adhesion IC50 = 4 nM/α4β1, 2 μM/α4β7, >100 μM/α1β1, α5β1, α6β1, αLβ2, αIIBβ3) based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) of fibronectin (aa 1980-1983). In addition to probing α4β1-mediated cellular responses, BIO 1211 is also widely used in animal disease models in vivo, including MS (5-10 mg/kg; murine EAE) and asthma (1-10 mg/kg via intranasal or nebulizer to mice, rats, sheep; 3 mg/sheep iv.).
Potent and selective α4β1 integrin (VLA-4) antagonist for probing α4β1-mediated cellular & pathological responses in vitro and in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
常规特殊物品
此项目有
K c Lin et al.
Journal of medicinal chemistry, 42(5), 920-934 (1999-03-12)
Integrin alpha4beta1 mediates leukocyte recruitment, activation, mediator release, and apoptosis inhibition, and it plays a central role in inflammatory pathophysiology. High-affinity, selective inhibitors of alpha4beta1, based on the Leu-Asp-Val (LDV) sequence from the alternatively spliced connecting segment-1 (CS-1) peptide of
Gloria C Koo et al.
American journal of respiratory and critical care medicine, 167(10), 1400-1409 (2003-02-06)
A nonpeptidyl small molecule antagonist, compound A, to nonactivated very late antigen-4 (VLA4) was examined in lung inflammation induced by a single dose of ovalbumin challenge. Compound A presented a good pharmacokinetic property, when given intratracheally, and the blood cells
Nourollah Ramroodi et al.
Immunological investigations, 44(7), 694-712 (2015-10-06)
Some functional limitations and economic burden of therapeutic antibodies indicated that introducing of alternative therapeutic compounds with same or different mechanism of action could be worthwhile. In this regard small-molecule antagonists can have a wide range of impacts, so in
Wei-Sheng Chen et al.
Nature communications, 7, 11302-11302 (2016-04-14)
Lymphangiogenesis plays a pivotal role in diverse pathological conditions. Here, we demonstrate that a carbohydrate-binding protein, galectin-8, promotes pathological lymphangiogenesis. Galectin-8 is markedly upregulated in inflamed human and mouse corneas, and galectin-8 inhibitors reduce inflammatory lymphangiogenesis. In the mouse model
W M Abraham et al.
American journal of respiratory and critical care medicine, 162(2 Pt 1), 603-611 (2000-08-10)
The leukocyte integrin very late antigen-4 (alpha(4)beta(1), CD49d/CD29) is an adhesion receptor that plays an important role in allergic inflammation and contributes to antigen-induced late responses (LAR) and airway hyperresponsiveness (AHR). In this study, we show that single doses of
我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持